odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
6169
10.69690/ODMJ-001-1230-6169
Original Research
Pancreatic Cancer in Guatemala: Socioeconomic Challenges in Latin America, Survival, and Palliative Care
https://orcid.org/0009-0003-7049-7059
Musús
Edras Samuel Hernández
Resident in Internal Medicine, Instituto Guatemalteco de Seguridad Social, Hospital General de Enfermedades, Universidad de San Carlos de Guatemala
esdrassamuelhm@gmail.com
Quiñonez
Julia Milagro Ovalle
Pathology Department, Instituto Guatemalteco de Seguridad Social, Hospital General de Enfermedades (IGSS)
Escobar
Allan Antonio Vargas
Resident in Internal Medicine, Instituto Guatemalteco de Seguridad Social, Hospital General de Enfermedades, Universidad de San Carlos de Guatemala
Fallas
Rixci Augusto Ramírez
Department of Oncology, Instituto Guatemalteco de Seguridad Social, Hospital General de Enfermedades
30
12
2025
ODMJ-001-1230-6169
Copyright (c) 2025 OncoDaily Medical Journal
2025
OncoDaily Medical Journal
Guatemala
Palliative Care
Pancreatic Cancer
Socioeconomic Challenges
production-ready-file-url
[
Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10‑45
]
[
Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605‑17.
]
[
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‑49.
]
[
Cáceres de León P. Perfil epidemiológico de los pacientes con cáncer de páncreas en el INCAN: estudio retrospectivo-descriptivo 1988–1999 [Tesis de licenciatura en Internet]. Guatemala: Universidad de San Carlos de Guatemala, Facultad de Ciencias Médicas; 2002.
]
[
Ramírez RA, Rosales DE. Current perspective of gastro‑intestinal cancer in Guatemala. Onco Daily Med J. 2025;2(7):4309.
]
[
Tempero MA, Malafa MP, Al‑Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439‑57.
]
[
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817‑25.
]
[
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703.
]
[
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with non-colorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10.
]
[
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-27.
]
[
Hammel P, Van Cutsem E, Macarulla T, et al. Adjuvant FOLFIRINOX for pancreatic cancer: a standard of care in Europe? Updated results from the PRODIGE 24/CCTG PA.6 trial. J Clin Oncol. 2018;36(15):e16260.
]
[
Conroy T, Hammel P, Hebbar M, et al. PRODIGE 24/CCTG PA.6: a randomized trial of adjuvant mFOLFIRINOX versus gemcitabine in resected pancreatic adenocarcinoma — final results. J Clin Oncol. 2018;36(18):LBA4001.
]
[
Carrasco G, Flores L, Benites J, et al. Sobrevida del adenocarcinoma ductal de páncreas. Rev Gastroenterol Peru. 2022;42(3):201-208.
]
[
Noel M, Fiscella K. Disparities in pancreatic cancer treatment and outcomes. Health Equity. 2019;3(1):532-540.
]
[
Padhy AS, Puvvada R, Nittala R, Menon VS, Arora SR, Basani M. Analysis of short-term outcomes of pancreatic resections from a low-volume centre in a Tier II city in India. Indian J Surg Oncol. 2025;1-9.
]
[
Argüello Arias PT. Cáncer de páncreas. Revisión de tema. Rev Col Gastroenterol. 2006;21(3):190-195.
]
[
Liu W, Rao L, Qiao Z, Wang G, Li B, Shen G. Global disparities in the burden of pancreatic cancer (1990–2021): insights from the 2021 Global Burden of Disease study. BMC Cancer. 2025;25(1):722.
]